F. Ricciardolo (Orbassano (TO), Italy), I. Satia (Hamilton (ON), Canada)
Late Breaking Abstract - Dose-dependent inactivation of airway tryptase with a novel dissociating anti-Tryptase antibody (MTPS9579A) in healthy volunteers
T. Staton (South San Francisco, United States of America), S. Sukumaran (South San Francisco, United States of America), S. Rymut (South San Francisco, United States of America), G. Sperinde (South San Francisco, United States of America), M. Bremer (South San Francisco, United States of America), V. Steffen (South San Francisco, United States of America), P. Banerjee (South San Francisco, United States of America), F. Cai (South San Francisco, United States of America), J. Smith (South San Francisco, United States of America), H. Rhee (South San Francisco, United States of America), P. Belloni (South San Francisco, United States of America), J. Lin (South San Francisco, United States of America)
|  |
Late Breaking Abstract - An assessment of potential predictive biomarkers for the treatment of severe eosinophilic asthma with CRTH2 antagonists
Y. Ye (Oxford, United Kingdom), R. Shrimanker (Oxford, United Kingdom), P. Batty (Oxford, United Kingdom), K. Borg (Oxford, United Kingdom), C. Connolly (Oxford, United Kingdom), S. Thulborn (Oxford, United Kingdom), J. Cane (Oxford, United Kingdom), G. Hynes (Oxford, United Kingdom), T. Hinks (Oxford, United Kingdom), J. Steiner (Oxford, United Kingdom), S. Vinall (Abingdon, United Kingdom), M. Hunter (Abingdon, United Kingdom), R. Pettipher (Abingdon, United Kingdom), L. Xue (Oxford, United Kingdom), I. Pavord (Oxford, United Kingdom)
|  |
Late Breaking Abstract - Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma
I. Bruns (Boston, United States of America), M. Fitzgerald (Boston, United States of America), G. Mensing (Boston, United States of America), M. Tsung (Boston, United States of America), K. Pardali (Gothenburg, Sweden), P. Gardiner (Gothenburg, Sweden), D. Keeling (Gothenburg, Sweden), L. Axelsson (Gothenburg, Sweden), M. Olsson (Gothenburg, Sweden), C. Ghobadi (Gothenburg, Sweden), O. Walsh (Melbourne, Australia), K. Mclendon (Herston, Australia), N. Farinola (Adelaide, Australia), L. Hatchuel (Nedlands, Australia), D. Close (Cambridge, United Kingdom)
| |
Late Breaking Abstract - The impact of regular bisoprolol on recovery with salbutamol in asthma; a double-blind randomised controlled trial
M. Bennett (Hamilton, New Zealand), B. Hancox (Dunedin, New Zealand), C. Chang (Hamilton, New Zealand), C. Tuffery (Hamilton, New Zealand), S. Hopping (Hamilton, New Zealand)
| |
Late Breaking Abstract - Difference in clinical outcomes between smoking and non-smoking asthma patients who initiated an ICS or ICS/LABA treatment
K. Kostikas (Ioannina, Greece), E. Loefroth (Kista, Sweden), I. Kottakis (Basel, Switzerland), P. Mcgettigan (Dublin, Ireland), M. Mcsharry (Dublin, Ireland), H. Cao (East Hanover, United States of America)
| |
Phase 1 trial of a novel chemokine inhibitor
A. Renner (Vienna, Austria), K. Marth (Vienna, Austria), H. Schmutz (Tulln, Austria), J. Romanova (Tulln, Austria), B. Ferko (Tulln, Austria), W. Pohl (Vienna, Austria)
| |
Markers of eosinophilic inflammation are associated with response to the DP2 antagonist GB001 in patients with mild atopic asthma
H. Ortega (San Diego, United States of America), M. Fitzgerald (Boston, United States of America), K. Raghupathi (San Diego, United States of America), C. Tompinks (San Diego, United States of America), D. Singh (Manchester, United Kingdom)
| |
Efficacy and safety of VR475 (budesonide suspension delivered by the VR475 Inhalation System) as add-on treatment in patients with severe asthma (CLEARCUT Study)
T. Harrison (Nottingham, United Kingdom), J. Young (Chippenham, United Kingdom), A. Scrimgeour (Chippenham, United Kingdom), S. Du Toit (Chippenham, United Kingdom), R. Surujbally (Chippenham, United Kingdom), G. Burgess (Chippenham, United Kingdom)
| |
Exacerbation risk after night-time waking due to asthma in SYGMA 1
H. Reddel (Sydney, Australia), E. Bateman (Cape Town, South Africa), J. Fitzgerald (Vancouver, Canada), P. Barnes (London, United Kingdom), N. Zhong (Guangzhou, China), R. Lamarca (Barcelona, Spain), M. Puu (Gothenburg, Sweden), V. Alagappan (Gaithersburg, United States of America), G. Whelan (Gaithersburg, United States of America), P. O'Byrne (Hamilton, Canada)
| |
Number needed to treat (NNT) to have an additional patient free from a severe or moderate/severe exacerbation: post-hoc analysis of SYGMA 1 in mild asthma
M. Fitzgerald (Vancouver, Canada), P. O'Byrne (Hamilton, Canada), E. Bateman (Cape Town, South Africa), P. Barnes (London, United Kingdom), N. Zhong (Guangzhou, China), V. Alagappan (Gaithersburg, United States of America), G. Whelan (Gaithersburg, United States of America), R. Lamarca (Barcelona, Spain), M. Puu (Gothenburg, Sweden), H. Reddel (Sydney, Australia)
| |
Bronchial Thermoplasty Global Registry: Two Year Results
A. Torrego Fernandez (Barcelona, Spain), F. Herth (Heidelberg, Germany), A. Munoz (Barcelona, Spain), L. Puente (Madrid, Spain), P. Benedetti (Madrid, Spain), N. Facciolongo (Reggio Emillia, Italy), S. Bicknell (Glasgow, United Kingdom), M. Novali (Brescia, Italy), S. Gasparini (Ancona, Italy), M. Bonifazi (Ancona, Italy), K. Dheda (Cape Town, South Africa), F. Andreo (Barcelona, Spain), J. Vortuba (Prague, Czech Republic), D. Langton (Frankston, Australia), J. Flandes (Madrid, Spain), D. Fielding (Brisbane, Australia), P. Bonta (Amsterdam, Netherlands), D. Skowasch (Bonn, Germany), C. Schulz (Regensburg, Germany), K. Darwiche (Essen, Germany), F. Nolan (Marlborough, United States of America), R. Niven (Manchester, United Kingdom)
| |
Bronchial Thermoplasty leads to rapid and persistent improvements in airway remodeling
R. Russell (Leicester, United Kingdom), M. Aubier (Paris, France), M. Pretolani (Paris, France), M. Laviolette (Quebec, Canada), J. Chakir (Quebec, Canada), P. Bonta (Amsterdam, Netherlands), J. Annema (Amsterdam, Netherlands), P. Howarth (Southampton, United Kingdom), P. Chanez (Marseille, France), R. Chaudhuri (Glasgow, United Kingdom), A. Singapuri (Leicester, United Kingdom), L. Chachi (Leicester, United Kingdom), D. Stolz (Basel, Switzerland), D. Schumann (Basel, Switzerland), M. Castro (St Louis, United States of America), C. Brightling (Leicester, United Kingdom)
| |
Effect of extrafine medium strength (MS) ICS-containing triple therapy on exacerbations in asthmatics with persistent airflow limitation: A post-hoc analysis of the TRIMARAN study
J. Virchow (Rostock, Germany), P. Paggiaro (Pisa, Italy), W. Canonica (Milan, Italy), P. Kuna (Lodz, Poland), M. Kots (Parma, Italy), S. Corre (Parma, Italy), A. Vele (Parma, Italy), G. Georges (Parma, Italy), S. Petruzzelli (Parma, Italy)
| |
Indacaterol/glycopyrronium/mometasone furoate combination consistently shows lung function benefits in patients with asthma
K. Chapman (Toronto, Canada), H. Watz (Grosshansdorf, Germany), J. Beier (Wiesbaden, Germany), D. Singh (Manchester, United Kingdom), J. Hohlfeld (Hannover, Germany), Z. Diamant (Lund, Sweden), V. Scholz (Berlin, Germany), A. Sarkar (Oberhaching, Germany), I. Jones (Basel, Switzerland), R. Li (Beijing, China), P. Pinot (Basel, Switzerland), H. Tillmann (Basel, Switzerland)
| |
Are SABA-reliant asthma patients receiving adequate ICS therapy? A nationwide cohort study in Sweden (HERA)
M. Ekstrom (Lund, Sweden), B. Nwaru (Gothenburg, Sweden), L. Hasvold (Sodertalje, Sweden), F. Wiklund (Uppsala, Sweden), G. Telg (Sodertalje, Sweden), C. Janson (Uppsala, Sweden)
| |
Efficiency of extrafine beclometasone dipropionat/formoterol fumarate in asthma patients with cold and/or osmotic airway hyperresponsiveness (AHR)
J. Perelman (Blagoveshchensk, Russian Federation), A. Prikhodko (Blagoveshchensk, Russian Federation), E. Kochegarova (Blagoveshchensk, Russian Federation), L. Oshur (Blagoveshchensk, Russian Federation), E. Afanaseva (Blagoveshchensk, Russian Federation)
| |
Which traits to target in asthma? Importance of treatable traits varies depending on desired outcome
J. Fingleton (Wellington, New Zealand), J. Hardy (Wellington, New Zealand), C. Baggott (Wellington, New Zealand), S. Mane (Wellington, New Zealand), M. Weatherall (Wellington, New Zealand), R. Beasley (Wellington, New Zealand)
| |
Exploratory trial on cough reflex sensitivity in patients with acute cough during URTI and post recovery.
C. Wright (Cottingham, United Kingdom), S. Thackray-Nocera (Cottingham, United Kingdom), A. Morice (Cottingham, United Kingdom)
| |